Published on January 21, 2020
Eligible patients had metastatic Renal Cell Carcinoma (RCC), Endometrial Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Melanoma, Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer.
At 24 weeks, this is the percentage of patients that were still responding to the combination and their cancer has stopped from continuous growing and/or has shrunk:
- 63% of Renal Cell Cancer patients
- 52% of Endometrial Cancer patients
- 48% of Melanoma patients
- 36% SCCHN
- 33% NSCLC
- 25%Urothelial Cancer
The most common treatment-related adverse events were fatigue (58%), diarrhea (52%), hypertension (47%), and hypothyroidism (42%).
Contact us to find out what is the best treatment for YOU
Do not give up on life!
Contact us 24/7 for free service matching:
Call center +44.2082.426.039